Clinical trials: Renal Dysfunction
Hepatic Impairment, Renal Impairment
A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of zibotentan in patients with moderate hepatic and moderate renal impairment in comparison to a matched healthy control group.
- Trial name
- NCT05112419
- Testing
- Zibotentan
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Any Condition Underlying Critical Illness
SWedish Intensive Care Biobank
The goal of this observational study is to understand the genetic and molecular risk factors for developing critical illness in adult intensive care unit (ICU) patients in Sweden.
- Trial name
- SWIC-B (NCT07582601)
- Volunteers
- 25,000 people
- Sponsor
- Uppsala University
Acute Kidney Injury
Neutrophil Gelatinase Associated Liocalin in Predicting AKI in Coronary Artery Disease
The aim of this work is to assess the clinical significance of serum levels of neutrophil gelatinase-associated lipocalin (NGAL) to predict AKI in patients exposed to PCI.
- Trial name
- NCT03266367
- Testing
- Neutrophil gelatinase-associated lipocalin (NAGL)
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Assiut University
Heart Failure, Type 2 Diabetes
Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease
This study will be a prospective randomized implementation trial for patients hospitalized with heart failure, chronic kidney disease, and/or type 2 diabetes mellitus within Duke University Medical Center.
- Conditions
- Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
- Trial name
- IMPLEMENT-CRM (NCT05781334)
- Testing
- Virtual Consult Intervention
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Duke University
Peritoneal Lesion
NGAL, an Early Predictive Marker of Acute Kidney Injury After Cardiac Surgery in Neonates and Infants
Urinary NGAL has been shown to be an early marker of acute kidney injury (AKI) following paediatric cardiac surgery (2 hours off pump).
- Trial name
- NGAL (NCT01219998)
- Where
- France
- Volunteers
- 205 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Clinical Pharmacology
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
BAY 63-2521 is intended to be used for a disease that affects the blood flow through the lungs. Renal impairment is a common condition in patients with this disease.
- Trial name
- NCT04364464
- Testing
- Riociguat (Adempas, BAY 63-2521)
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Renal Failure
Dexmedetomidine and Renal Transplants
Investigators aim to retrospectively research patients undergoing renal transplants that received dexmedetomidine perioperatively to see if dexmedetomidine use protects renal function.
- Trial name
- NCT02019121
- Where
- United States
- Volunteers
- 797 people
- Sponsor
- University of California, Davis
End-stage Renal Disease, Hemodialysis Access Failure
Arteriovenous Fistula Maturation Evaluation Study. FAME Study
Study of the features of hemodynamic and clinical maturation of the native arteriovenous fistula for hemodialysis.
- Conditions
- End-stage Renal Disease, Hemodialysis Access Failure, Vascular Access Maturation, Native Arteriovenous Fistula
- Trial name
- NCT04736875
- Testing
- Doppler ultrasound study
- Where
- Greece
- Volunteers
- 86 people
- Sponsor
- Medifil AE
Renal Insufficiency
Clinical Assessment of a New Catheter Surface Coating With Antimicrobial Properties
The study investigates the efficacy of a catheter with antibacterial surface coating in preventing central venous catheter related infection and the effect of an intensive hygiene and catheter care education of the nursing staff…
- Trial name
- NCT00621712
- Testing
- GamCath® central venous catheter, GamCath Dolphin® Protect central venous catheter
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Vantive Health LLC
Chronic Kidney Diseases, High Cholesterol
Evolocumab In Advanced Chronic Kidney Disease Trial
110 individuals with stage 4-5 Chronic Kidney Disease (CKD) will be randomized to 1-year of blinded Evolocumab or placebo. Subjects will undergo evaluation of circulating lipids at baseline and end of study.
- Trial name
- EVO-CKD (NCT04510844)
- Testing
- Evolocumab
- Where
- 2 sites in United States
- Sponsor
- NYU Langone Health
Hemodialysis Patients
Effects of Exercise Program on Physical Functioning of Hemodialysis Patients.
This study is designed to provide a simple, home-based, low-moderate intensity exercise program in chronic renal disease patients who are undergoing hemodialysis in order to improve physical performance, decrease the level of…
- Trial name
- NCT04674930
- Testing
- Exercise program
- Where
- Pakistan
- Volunteers
- 26 people
- Sponsor
- Riphah International University
End-Stage Renal Disease
Vitamin D3 Supplementation in Dialysis Patients
Vitamin D deficiency is highly prevalent among dialysis patients, and has been associated with cardiovascular risk factors such as increased aortic pulse wave velocity, blood pressure, inflammation, and brain natriuretic peptide.
- Trial name
- NCT01312714
- Testing
- Cholecalciferol
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- Regional Hospital Holstebro
Ovarian Cysts, Chronic Renal Insufficiency
Anti-inflammatory Cells in Peritoneal Cavity
Some subsets of lymphocytes are able to inhibit immune response and thus, could be used to control auto-immune diseases and transplant reject.
- Trial name
- NCT03189316
- Testing
- peritoneal fluid and blood sample
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Montpellier
Kidney Dysfunction
Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function
This is a single center, open-label, non-randomized, 1:1 parallel control and single dose administration study design. Healthy subjects will be matched to severe renal function impaired (eGFR≤30mL/min/1.73m2，CKD-EPI estimated)…
- Trial name
- NCT02840812
- Testing
- Nemonoxacin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Zhejiang Medicine Co., Ltd.
Renal Replacement Therapy, Acute Kidney Injury
Saline Versus Albumin Fluid for Extracorporeal Removal With Slow Low Efficiency Dialysis Feasibility Study
Objective: The primary aim of this 60 patient feasibility trial is to determine if, for critically ill patients treated with SLED for AKI, randomization to receive albumin (25%) boluses versus normal saline placebo boluses is…
- Conditions
- Renal Replacement Therapy, Acute Kidney Injury, Hypotension
- Trial name
- SAFER-SLED (NCT03665311)
- Testing
- 25% Albumin fluid, Normal Saline
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Ottawa Hospital Research Institute
Renal Impairment
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100
- Trial name
- NCT05086107
- Testing
- BV100
- Where
- Hungary
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- BioVersys AG
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
End Stage Kidney Disease
Effect of 25-hydroxyvitamin D and a Structured Exercise Program on Dialysis Patients
This study aims to examine the effect of 25 hydroxyvitamin D supplementation and a structured exercise program on the exercise capacity and quality of life of haemodialysis patients with 25 hydroxyvitamin D insufficiency.
- Trial name
- NCT00798993
- Testing
- Structured Exercise program, Cholecalciferol (25-Hydroxyvitamin D), Usual exercise
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Sir Charles Gairdner Hospital
Anemia
Treatment of Anemia in Diabetic Subjects With CKD
The purpose of this study is to compare the proportion of subjects receiving either Epoetin alfa (PROCRIT®) or placebo who are able to achieve a hemoglobin response, defined by at least a 1 gram/deciliter increase from baseline…
- Trial name
- NCT00240734
- Testing
- Epoetin alfa
- Volunteers
- 11 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Vitamin D Deficiency, End-stage Renal Disease
Impact of Vitamin D Repletion in Hemodialysis Patients
Dialysis patients often suffer from defects in their immune system (that part of the body which fights infection). Evidence suggests that Vitamin D deficiency may have a negative effect on immunity, and many dialysis patients are…
- Trial name
- NCT01175798
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Mehrotra, Anita, M.D.